Pehrson, Isabelle
Sayyab, Shumaila
Das, Jyotirmoy
Idh, Nina
Paues, Jakob
Méndez-Aranda, Melissa
Ugarte-Gil, César
Lerm, Maria
Funding for this research was provided by:
Consejo Nacional de Ciencia, Tecnología e Innovación Tecnológica (106-2018-FONDECYT)
Forskningsrådet i Sydöstra Sverige (FORSS-932096)
Vetenskapsrådet (2015-02593)
Hjärt-Lungfonden (20150709)
Linköping University
Article History
Received: 15 June 2022
Accepted: 29 November 2022
First Online: 17 December 2022
Declarations
:
: Included subjects donated peripheral blood and induced sputum samples following oral and written informed consent. Ethical approval for Sweden was obtained from the Regional Ethics Review Board in Linköping, (2016/237-31) and for Peru from the Institutional Committee on Research Ethics of the Cayetano Heredia National Hospital for the inclusion of patients (082-018) and by Universidad Peruana Cayetano Heredia Institutional Review Board for the inclusion of healthy subjects (101773). The study protocol included questionnaires on respiratory and overall health, the evaluation of IGRA status and sputum samples for DNA extraction. The subjects’ samples and questionnaires were not linked to any personal information at any stage of the study. The sputum sample collections were performed in accordance with guidelines from the Department of Respiratory Medicine at Linköping University Hospital. In Sweden, the IGRA samples (QuantiFERON-TB Gold) were collected and analysed by medical personnel according to the guidelines at the Department of Clinical Microbiology at Linköping University Hospital. In Peru, the IGRA samples (T-SPOT.TB) was taken and analysed by medical students under supervision.
: Not applicable.
: The authors declare that they have no competing interests.